Vistin Pharma results for the third quarter and year-to-date 2026 will be released on Thursday, October 29, the Norwegian pharmaceutical company announced on October 21. A conference call for shareholders and other interested parties is scheduled for the same day at 08:30 CET.
Key Takeaways
- The October 29 release will cover both third-quarter and year-to-date 2026 results.
- Management’s discussion will be followed by a question-and-answer session.
- Investors can join through a webcast or a telephone conference with online registration.
Table of Contents
Vistin Pharma results schedule confirmed
The company’s third-quarter conference call announcement sets out the timetable for the release and accompanying management discussion. The invitation contains no revenue, profit or earnings guidance, so it does not establish how the business performed during the reporting period.
The quarterly and year-to-date figures will provide separate views of the latest three months and cumulative 2026 performance. Both remain scheduled disclosures rather than results already published in the invitation.
| Item | Details |
|---|---|
| Headquarters | Oslo, Norway |
| Manufacturing facility | Kragerø, Norway |
| Company ticker | VISTN |
How shareholders can follow the discussion
Vistin Pharma has provided web and audio access arrangements for the October 29 call. Telephone participants can register online, while the webcast offers a separate way to follow management’s presentation.
The Q&A will take place after management’s discussion. The invitation is open to all shareholders and interested parties, rather than a restricted investor group.
Vistin Pharma produces metformin hydrochloride, an active pharmaceutical ingredient, and also offers metformin as direct-compressible lubricated granules. Its corporate and manufacturing locations are outlined below.
Conclusion
The next confirmed event is the October 29 results release and accompanying conference call, when management is scheduled to discuss the figures and take questions.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
